Collaboration, License, and Supply Agreements - Pfizer (Details) $ in Millions |
1 Months Ended | 3 Months Ended | |
|---|---|---|---|
|
Jan. 31, 2026
USD ($)
|
Mar. 31, 2026 |
Jan. 30, 2026
disease_area
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Number of disease areas | disease_area | 2 | ||
| Pfizer Inc | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Upfront payment | $ 30 | ||
| Maximum developmental and sales milestone payments | 500 | ||
| Pfizer | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Development milestone payments | 70 | ||
| Sales milestone payments | $ 180 | ||
| Development and sales milestone payments, term | 20 years |